Hepatocyte-like cells derived from induced pluripotent stem cells: A versatile tool to understand lipid disorders

Dyslipidemias are strongly linked to the development of atherosclerotic cardiovascular disease. Most dyslipi- demias find their origin in the liver. In recent years, the differentiation of induced pluripotent stem cells (iPSCs) into hepatocyte-like cells has provided a versatile platform for the functional study of various dyslipidemias, both rare genetic dyslipidemia as well as common lipid disorders associated with insulin resistance or non- alcoholic fatty liver disease. In addition, iPSC-derived hepatocytes can serve as a cell model for developing novel lipid lowering therapies and have the potential of regenerative medicine. This review provides an overview of these developments.